Prediction for the occurrence of superimposed preeclampsia according to significant variables selected by logistic regression analysis at booking.

<p>SE: sensitivity, SP: specificity, PPV: positive predictive value, NPV: negative predictive value, LR: likelihood ratio.</p><p>Composite variable 1and 2: all both are present: previous preeclampsia, MAP≥95 mmHg.</p><p>Composite variable 1or2: at least one of: previous preeclampsia, MAP≥95 mmHg.</p

Maternal and perinatal outcomes of 211 women with essential chronic hypertension.

*<p>Causes of delivery <34 wks: 19 for PE, and 20 for other reasons (12 abnormal fetal heart rate monitoring with FGR, 1 abruption, 4 pregnancy terminations for fetal death, 2 preterm premature rupture of membranes, and 1 pregnancy termination for very severe FGR at 28 weeks’ gestation with birth weight at 450 g).</p>†<p>5 fetal deaths, 2 fetal terminations [1 for very severe FGR (see above) and 1 for very early onset of severe preeclampsia at 22 weeks’ gestation], and 1 neonatal death.</p

Perinatal outcomes according to the occurrence of superimposed preeclampsia.

<p>PE: superimposed preeclampsia.</p

Factors associated with development of superimposed preeclampsia by univariate and multivariate^* analysis at first prenatal visit.

*<p>logistic regression analysis performed for variables with a p<.1 at univariate analysis at booking; PE: superimposed preeclampsia.</p

Association of <i>CORIN</i> rs2271036 and rs2271037 single nucleotide polymorphisms (SNPs) with preeclampsia (PE).

<p>Results are given in the discovery (S1), replication (S2) and combined (C) samples, in Caucasian subjects from Europe (Eur), Maghreb (Mgh) or Sub-Saharan-African subjects (Afr).</p><p><b>*</b>Genotypes are expressed as percentage (number) of patients with TT/TC/CC genotype for rs2271036 and as TT/TG/GG genotype for rs2271037, respectively.</p>†<p>ORs (95% IC, p values) calculated in a dominant model, adjusted for nulliparity and obesity, associated with the (CC+CT) versus the TT genotype (rs2271036) or with the (GG+GT) versus the TT genotype (rs2271037). MAF, minor allele frequency.</p>‡<p>Significantly different when compared to the control group (chi-square test adjusted for nulliparity and obesity).</p><p>Association of <i>CORIN</i> rs2271036 and rs2271037 single nucleotide polymorphisms (SNPs) with preeclampsia (PE).</p

Flow chart for the enrollment of the study population and the SNP analysis.

<p>Flow chart for the enrollment of the study population and the SNP analysis.</p

Quality control for the 19 <i>CORIN</i> single nucleotide polymorphisms (SNPs) found in the discovery sample (sample 1, n = 260).

<p>For each SNP, position on chromosome 4, minor allele frequencies (MAF) in both ethnic groups of subjects and results of testing for departure from Hardy Weinberg equilibrium (<i>p</i> (HWE)). Both SNPs of interest (rs2271036 and rs2271037) are in bold. SNPs with MAF below 1% in Caucasians are in italics.</p><p>del, deletion.</p><p>*Caucasian from Europe or Maghreb.</p>†<p>Sub-Saharan African patients.</p>‡<p>Genotypic association with preeclampsia in a dominant model: conditional logistic regression analysis adjusted for nulliparity and obesity.</p><p>Quality control for the 19 <i>CORIN</i> single nucleotide polymorphisms (SNPs) found in the discovery sample (sample 1, n = 260).</p

PlGF values at inclusion according to pregnancy outcome.

<p>PlGF values are expressed as mean ± standard deviation.</p>*<p>37/38 patients had an adverse outcome, t-test could not be applied.</p>†<p>among patients enrolled <34 weeks of gestation.</p><p><b>adverse outcome</b> is defined by severe preeclampsia, or birthweight <10^th centile for gestational age, or elective cesarean section for maternal or fetal disease; <b>severe adverse outcome</b> is defined among patients included <34 weeks of gestation, by HELLP syndrome, or eclampsia, or stillbirth or termination of pregnancy, or birthweight <3^rd centile for gestational age, or elective cesarean delivery <34 weeks of gestation for maternal or fetal disease.</p

ROC curves for the prediction of adverse outcome and severe adverse outcome.

<p>SBP : Systolic blood pressure; PlGF is expressed in pg/mL. Prediction of severe adverse outcome is calculated among 65 patients who were enrolled <34 weeks of gestation. Area under the curve (AUC) values are indicated next to each predictor.</p

Human endogenous retrovirus-FRD envelope protein (syncytin 2) expression in normal and trisomy 21-affected placenta-4

<p><b>Copyright information:</b></p><p>Taken from "Human endogenous retrovirus-FRD envelope protein (syncytin 2) expression in normal and trisomy 21-affected placenta"</p><p>http://www.retrovirology.com/content/5/1/6</p><p>Retrovirology 2008;5():6-6.</p><p>Published online 23 Jan 2008</p><p>PMCID:PMC2245979.</p><p></p>cells (CT). No immunostaining was observed in the syncytiotrophoblast (ST) and in the mesenchymal core (MC). Scale bar = 10 μm. This large magnification allows to clearly establish the cytoplasmic localization of syncytin 2 immunostaining in a pair of cytotrophoblastic cells. At this gestational age the cytotrophoblast consists of a continuous single layer of cuboidal cells beneath the syncytiotrophoblast. Scale bar = 10 μm. Arrowhead: non labeled CT, arrow: positively stained CT. Middle panel. Second trimester placenta (16 weeks of pregnancy). Immunostaining with anti-syncytin2 antibody shows positive reactivity in some cytotrophoblastic cells. No syncytin 2 reactivity was detected in the extravillous trophoblast (ECT), in the syncytiotrophoblast and in the mesenchymal core. Scale bar = 10 μm. In this floating villi, syncytin 2 immunostaining was observed in the cytoplasm of some cytotrophoblastic cells (arrow), in their thin cytoplasmic processes (star) and at the level of the trophoblastic basal lamina (double head arrow). Scale bar = 10 μm. Bottom panel. Term placenta floating villi. Syncytin 2 was detected in the cytoplasm surrounding the nuclei of flat cytotrophoblastic cells and in their thin elongated cytoplasmic processes. Staining was absent from some villi. Scale bar = 10 μm. This large magnification allows to clearly establish the syncytin 2 immunostaining continuity within cytotrophoblasts between the cytoplasm surrounding the nuclei and that of the thin cytoplasmic processes. Scale bar = 10 μm